Живи долго! Научный подход к долгой молодости и здоровью - Майкл Грегер

https://pubmed.ncbi.nlm.nih.gov/34649336/

5932

Mandlik (Ingawale) DS, Namdeo AG. Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl. 2021;18(2):183–226. https://pubmed.ncbi.nlm.nih.gov/32242751/

5933

Dongre S, Langade D, Bhattacharyya S. Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving sexual function in women: a pilot study. Biomed Res Int. 2015;2015:284154. https://pubmed.ncbi.nlm.nih.gov/26504795/

5934

Ashwagandha. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. https://pubmed.ncbi.nlm.nih.gov/31643176/

5935

Simon JA, Lukas VA. Distressing sexual function at midlife: unmet needs, practical diagnoses, and available treatments. Obstet Gynecol. 2017;130(4):889–905. https://pubmed.ncbi.nlm.nih.gov/28885410/

5936

Portman DJ, Gass MLS, Kingsburg S, et al. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–8. https://pubmed.ncbi.nlm.nih.gov/25160739/

5937

Scavello I, Maseroli E, Di Stasi V, Vignozzi L. Sexual health in menopause. Medicina (Kaunas). 2019;55(9):559. https://pubmed.ncbi.nlm.nih.gov/31480774/

5938

Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–14. https://pubmed.ncbi.nlm.nih.gov/31378291/

5939

Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92(12):1842–9. https://pubmed.ncbi.nlm.nih.gov/29202940/

5940

Scavello I, Maseroli E, Di Stasi V, Vignozzi L. Sexual health in menopause. Medicina (Kaunas). 2019;55(9):559. https://pubmed.ncbi.nlm.nih.gov/31480774/

5941

Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92(12):1842–9. https://pubmed.ncbi.nlm.nih.gov/29202940/

5942

Herbenick D, Reece M, Hensel D, Sanders S, Jozkowski K, Fortenberry JD. Association of lubricant use with women’s sexual pleasure, sexual satisfaction, and genital symptoms: a prospective daily diary study. J Sex Med. 2011;8(1):202–12. https://pubmed.ncbi.nlm.nih.gov/21143591/

5943

Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med. 2018;178(5):681–90. https://pubmed.ncbi.nlm.nih.gov/29554173/

5944

Huang AJ, Grady D. Rethinking the approach to managing postmenopausal vulvovaginal symptoms. JAMA Intern Med. 2018;178(5):690–1. https://pubmed.ncbi.nlm.nih.gov/29554180/

5945

Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61. https://pubmed.ncbi.nlm.nih.gov/26707589/

5946

Adriaens E, Remon JP. Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis. 2008;35(5):512–6. https://pubmed.ncbi.nlm.nih.gov/18356773/

5947

Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61. https://pubmed.ncbi.nlm.nih.gov/26707589/

5948

Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61. https://pubmed.ncbi.nlm.nih.gov/26707589/

5949

Scavello I, Maseroli E, Di Stasi V, Vignozzi L. Sexual health in menopause. Medicina (Kaunas). 2019;55(9):559. https://pubmed.ncbi.nlm.nih.gov/31480774/

5950

Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92(12):1842–9. https://pubmed.ncbi.nlm.nih.gov/29202940/

5951

Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92(4 Pt 2):722–7. https://pubmed.ncbi.nlm.nih.gov/9764689/

5952

Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92(12):1842–9. https://pubmed.ncbi.nlm.nih.gov/29202940/

5953

Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500. https://pubmed.ncbi.nlm.nih.gov/27577677/

5954

. Šimunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Šprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003;82(2):187–97. https://pubmed.ncbi.nlm.nih.gov/12873780/

5955

Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med. 2018;178(5):681–90. https://pubmed.ncbi.nlm.nih.gov/29554173/

5956

Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446–5. https://pubmed.ncbi.nlm.nih.gov/31995690/

5957

Premarin® Vaginal Cream Boxed Warning (conjugated estrogens). Pfizer. https://www.pfizermedicalinformation.com/en-us/premarin-vaginal-cream/boxed-warning. Updated September 2018. Accessed August 24, 2022.; https://www.pfizermedicalinformation.com/en-us/premarin-vaginal-cream/boxed-warning

5958

Pinkerton JV, Kaunitz AM, Manson JE. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. Menopause. 2017;24(12):1329–32. https://pubmed.ncbi.nlm.nih.gov/29040220/

5959

Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2018;26(6):603–10. https://pubmed.ncbi.nlm.nih.gov/30562320/

5960

Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27(3):339–60. https://pubmed.ncbi.nlm.nih.gov/31913230/

5961

Kelsey JL, LiVolsi VA, Holford TR, et al. A case-control study of cancer of the endometrium. Am J Epidemiol. 1982;116(2):333–42. https://pubmed.ncbi.nlm.nih.gov/7114042/

5962

Mørch LS, Kjaer SK, Keiding N, Løkkegaard E, Lidegaard Ø. The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study. Int J Cancer. 2016;138(6):1506–15. https://pubmed.ncbi.nlm.nih.gov/26421912/

5963

Pinkerton JV, Kaunitz AM, Manson JE. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. Menopause. 2017;24(12):1329–32. https://pubmed.ncbi.nlm.nih.gov/29040220/

5964

Scavello I, Maseroli E, Di Stasi V, Vignozzi L. Sexual health in menopause. Medicina (Kaunas). 2019;55(9):559. https://pubmed.ncbi.nlm.nih.gov/31480774/

5965

Eden